Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „intermediate“
Suchtreffer
Begriffe & Kennungen
Abseamed · 4.8 · Adult patients with low- or intermediate-1-risk MDS In the randomised, double-blind, placebo-controlled, multi
Eintrag öffnenAhornsirupkrankheit
Eintrag öffnenAktiver Sauerstoff
Eintrag öffnenArsenic trioxide Accord · 4.8 · Haematological and gastrointestinal toxicity In newly diagnosed patients with low to intermediate risk APL, ga
Eintrag öffnenArsenic trioxide Accord · 4.8 · Hepatotoxicity (grade 3-4) In newly diagnosed patients with low to intermediate risk APL 63.2 % developed grad
Eintrag öffnenArsenic trioxide Accord · 4.8 · In newly diagnosed patients with low to intermediate risk APL, differentiation syndrome was observed in 19 % i
Eintrag öffnenArsenic trioxide Accord · 4.8 · In newly diagnosed patients, with low to intermediate risk APL, QTc prolongation was observed in 15.6 %. In on
Eintrag öffnenArsenic trioxide medac · 4.8 · In newly diagnosed patients with low to intermediate risk APL 63.2 % developed grade 3 or 4 hepatic toxic effe
Eintrag öffnenArsenic trioxide medac · 4.8 · In newly diagnosed patients with low to intermediate risk APL, differentiation syndrome was observed in 19 % i
Eintrag öffnenArsenic trioxide medac · 4.8 · In newly diagnosed patients with low to intermediate risk APL, gastrointestinal toxicity, grade 3-4 neutropeni
Eintrag öffnenArsenic trioxide medac · 4.8 · In newly diagnosed patients, with low to intermediate risk APL, QTc prolongation was observed in 15.6 %. In on
Eintrag öffnenBinocrit · 4.8 · Adult patients with low- or intermediate-1-risk MDS In the randomised, double-blind, placebo-controlled, multi
Eintrag öffnenCamzyos · 4.5 · 11 Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and u
Eintrag öffnenCamzyos · 4.5 · 12 Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and u
Eintrag öffnenCamzyos · 4.5 · Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate, medicinal product normal, rapid and ultr
Eintrag öffnenCamzyos · 4.5 · Effect of other medicinal products on mavacamten In CYP2C19 intermediate, normal, rapid and ultra-rapid metabo
Eintrag öffnenDynein-ATPase
Eintrag öffnenEpidermolysis bullosa simplex, generalisierte intermediäre, autosomal-dominante
Eintrag öffnenEpidermolysis bullosa, dystrophe, generalisierte, autosomal-rezessive, intermediäre Form
Eintrag öffnenEpidermolysis bullosa, junktionale, generalisierte intermediäre
Eintrag öffnen